Stryker
Sunshine Heart seeks $25.5M in equity funding round | Wall Street Beat
Eden Prairie, Minn., and Sydney-based medical device company Sunshine Heart (ASX:SHC) is looking to raise funds in a $25.5 million equity funding round, according to document filed with the SEC earlier this month.
Appetite for Acquisition: Stryker CEO Lobo says medical device company is in the hunt | Wall Street Beat
Sluggish results continue to roll in across the med-tech sector
Recall, DoJ probe push Stryker’s Q1 profits down 13%
Stryker (NYSE:SYK) said the recall of some of its hip implant components and a U.S. Justice Dept. probe into its OtisKnee device helped push 1st-quarter profits down 13%, but still managed to beat Wall Street analysts’ expectations.
Kalamazoo, Mich.-based Stryker posted profits of $304 million, or 79¢ per share, on sales of $2.19 billion during the quarter, amounting to 1.3% sales growth.
Stryker’s knee surgery device recall gets FDA’s highest-risk label
UPDATE: Details on ex-Denstply CFO Ellison’s jump to Stryker
Dentsply International (NSDQ:XRAY) detailed its plans to replace ex-CFO William Jellison, who jumped ship today for medical device company Stryker (NYSE:SYK).
FLASH: Stryker nabs Dentsply CFO Jellison
Medical device company Stryker (NYSE:SYK) said it hired William Jellison, the finance chief for Dentsply International (NSDQ:XRAY), to be its new CFO.
EndoStim takes funding round to $11M | Wall Street Beat
EndoStim added another tranche to its $16.5 million equity round, according to a regulatory filing, saying it’s added some $11.2 million to its coffers as it develops a pacemaker-like implant to treat gastro-esophageal reflux disease.